title: The renin-angiotensin system as a target of novel anticancer therapy.
abstract: The role of the renin-angiotensin system (RAS) in the development of various malignancies has recently been extensively examined and, since it has been shown to significantly influence many aspect of cancer initiation and progression, the idea of RAS-targeted anticancer therapy has arisen. This article reviews the mechanisms underlying RAS-induced physiological and pathological responses related to cancer biology, including tumor growth, cell proliferation, apoptosis, angiogenesis, inflammation, and protein degradation, emphasizing the associated cellular transduction schemes activated by main RAS effectors. Also the dual nature of RAS-dependent effects, resulting from its complex physiology has been commented. Finally, based on the available data from clinical trials and experimental studies, the possibilities of the introduction of RAS-modulating drugs into standard clinical practice in oncology have been discussed with the focus on both, positive and negative effects associated with the administration of various classes of pharmaceuticals to cancer patients.
authors.affiliation: Greater Poland Oncology Center, 15th Garbary Street, 61-866 Poznan, Poland. katarzyna.regulska@wco.pl.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Regulska
authors.forename: Beata
authors.initials: B
authors.lastname: Stanisz
authors.forename: Milosz
authors.initials: M
authors.lastname: Regulski
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D015195:Drug Design; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012084:Renin-Angiotensin System / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents